129 related articles for article (PubMed ID: 25109420)
1. Response to Bogaiksy's letter to the editor.
Freund-Levi Y; Jedenius E; Wahlund LO; Eriksdotter M; Tysen-Bäckström AC; Lärksäter M
Am J Geriatr Psychiatry; 2014 Sep; 22(9):951. PubMed ID: 25109420
[No Abstract] [Full Text] [Related]
2. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.
Bogaisky M
Am J Geriatr Psychiatry; 2014 Sep; 22(9):951. PubMed ID: 25109421
[No Abstract] [Full Text] [Related]
3. An unsubstantiated conclusion.
Reifler BV; Blazer D
Am J Geriatr Psychiatry; 2015 Feb; 23(2):220. PubMed ID: 25575935
[No Abstract] [Full Text] [Related]
4. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.
Freund-Levi Y; Jedenius E; Tysen-Bäckström AC; Lärksäter M; Wahlund LO; Eriksdotter M
Am J Geriatr Psychiatry; 2014 Apr; 22(4):341-8. PubMed ID: 24035407
[TBL] [Abstract][Full Text] [Related]
5. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.
Freund-Levi Y; Bloniecki V; Auestad B; Tysen Bäckström AC; Lärksäter M; Aarsland D
Dement Geriatr Cogn Disord; 2014; 38(3-4):234-44. PubMed ID: 24969380
[TBL] [Abstract][Full Text] [Related]
6. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
Holmes C; Wilkinson D; Dean C; Clare C; El-Okl M; Hensford C; Moghul S
Int J Geriatr Psychiatry; 2007 Apr; 22(4):380-1. PubMed ID: 17380475
[No Abstract] [Full Text] [Related]
7. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.
Workman RH; Orengo CA; Bakey AA; Molinari VA; Kunik ME
J Neuropsychiatry Clin Neurosci; 1997; 9(4):594-7. PubMed ID: 9447503
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury.
Bennouna M; Greene VB; Defranoux L
J Clin Psychopharmacol; 2005 Oct; 25(5):505-7. PubMed ID: 16160637
[No Abstract] [Full Text] [Related]
9. [Risperidone and cerebrovascular adverse effects in elderly patients with dementia].
Formiga F; Fort I; Pérez-Castejón JM; Ruiz D; Duaso E; Riu S
Rev Clin Esp; 2006 Sep; 206(8):411-2; author reply 412-3. PubMed ID: 16863635
[No Abstract] [Full Text] [Related]
10. Galantamine for treatment-resistant schizophrenia.
Allen TB; McEvoy JP
Am J Psychiatry; 2002 Jul; 159(7):1244-5. PubMed ID: 12091212
[No Abstract] [Full Text] [Related]
11. Risperidone for the treatment of behavioral disturbances in dementia: a case series.
Herrmann N; Rivard MF; Flynn M; Ward C; Rabheru K; Campbell B
J Neuropsychiatry Clin Neurosci; 1998; 10(2):220-3. PubMed ID: 9608413
[TBL] [Abstract][Full Text] [Related]
12. Licensed indication for risperidone in dementia.
Phizackerley D
BMJ; 2014 Dec; 349():g7337. PubMed ID: 25498536
[No Abstract] [Full Text] [Related]
13. Risperidone in the management of agitation in HIV dementia.
Lodge P; Tanner M; McKeogh MM
Palliat Med; 1998 May; 12(3):206-7. PubMed ID: 9743841
[No Abstract] [Full Text] [Related]
14. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
15. Trends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010.
Okumura Y; Togo T; Fujita J
Int Psychogeriatr; 2015 Mar; 27(3):407-15. PubMed ID: 25213318
[TBL] [Abstract][Full Text] [Related]
16. The effect of risperidone on nursing burden associated with caring for patients with dementia.
Asghar Ali AA; Espinoza R; Kavirajan H; Read S
J Am Geriatr Soc; 2005 Jul; 53(7):1261-2; author reply 1262-3. PubMed ID: 16108953
[No Abstract] [Full Text] [Related]
17. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Wadenberg ML; Fjällström AK; Federley M; Persson P; Stenqvist P
Int J Neuropsychopharmacol; 2011 Jun; 14(5):644-54. PubMed ID: 20701827
[TBL] [Abstract][Full Text] [Related]
18. Duration of risperidone treatment for BPSD.
Snowdon J; Brodaty H; Ames D; Day S
Int J Geriatr Psychiatry; 2006 Jul; 21(7):699-701. PubMed ID: 16821255
[No Abstract] [Full Text] [Related]
19. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Tune LE
J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
[TBL] [Abstract][Full Text] [Related]
20. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial.
Ghaleiha A; Ghyasvand M; Mohammadi MR; Farokhnia M; Yadegari N; Tabrizi M; Hajiaghaee R; Yekehtaz H; Akhondzadeh S
J Psychopharmacol; 2014 Jul; 28(7):677-85. PubMed ID: 24132248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]